Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
A Randomized, Parallel, Double-Blind Efficacy and Safety Study of Biphentin Methylphenidate HCl Extended Release Capsules Compared to Placebo in Children and Adolescents 6 to 18 Years With Attention Deficit Hyperactivity Disorder (ADHD)
Sponsor: Rhodes Pharmaceuticals, L.P.
This PHASE3 trial investigates ADHD and Attention Deficit Hyperactivity Disorder and is currently completed. Rhodes Pharmaceuticals, L.P. leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Mar 2023 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Rhodes Pharmaceuticals, L.P.
For direct contact, visit the study record on ClinicalTrials.gov .